AgeneBio is developing innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function.
Our Mission &
To discover and develop innovative therapeutics that preserve and restore brain function for patients at risk for neurodegeneration, benefiting the lives of patients, their families, and society as a whole.
Nearly every minute, someone in America transitions from normal aging when occasional senior moments of memory loss become an everyday part of life. This condition is called amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. For most people, their memory will worsen and within a few years, their condition will transition to Alzheimer’s dementia. Unfortunately, today there is no treatment for patients experiencing aMCI.
Decades of research show the the best prospect to prevent and delay progression to Alzheimer’s dementia is to intervene as early as possible, at the stage of aMCI. Currently, patients with aMCI have no treatment for their symptoms or therapy to prevent Alzheimer’s dementia. The goal of AgeneBio’s lead development program is to provide a solution to this unmet medical need.
Our science and intellectual property are based on decades of unparalleled research at Johns Hopkins and leading research centers worldwide demonstrating that overactivity in the hippocampus contributes to cognitive impairment and drives neurodegeneration if not controlled.
Our pipeline includes multiple candidates to treat patients with neurological and psychiatric disease.
Our lead candidate, AGB101, is Phase 3-ready, targeting the large unserved aMCI patient population. If approved, AGB101 will be the first and only therapeutic targeting hippocampus overactivity and potentially the first therapeutic to slow progression to, and delay the onset of, Alzheimer’s dementia. The HOPE4MCI Phase 3 trial is expected to initiate in 2H2015.